Analyses of zebrafish meioc mutants revealed that spermatogonial stem cells with low rRNA transcription caused by nucleolar Piwil1 require Meioc to keep Piwil1 in cytoplasm for the upregulation of ...

ProPhase Labs (PRPH) announced the closing of a private placement financing with two investors for $3 million in senior secured convertible notes ...

Detailed price information for Prophase Labs Inc (PRPH-Q) from The Globe and Mail including charting and trades.

Aktien»Nachrichten»PROPHASE LABS AKTIE»ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule PROPHASE LABS INC ...

UNIONDALE, NY - ProPhase Labs Inc. (NASDAQ:PRPH) has received a 180-day extension from Nasdaq to regain compliance with the exchange's minimum $1.00 bid price requirement, the biotech company ...

ProPhase Labs , Inc. (NASDAQ: PRPH) announced the appointment of Carolina Abenante, Esq. as an independent director to its Board of Directors, effective Friday. According to a statement based on a ...

Prophase will now move to accelerated commercialization of BE-Smart TM with expected clinical launch in the next 2-3 quarters.

Additionally, ProPhase Labs announced that Mayo Clinic's Dr. Chris Hartley has submitted a paper on their B-Smart Esophageal Cancer Test, highlighting its potential for commercialization.

ProPhase Labs Inc (PRPH) outlines cost reductions, promising cancer test developments, and strategic alternatives amidst financial hurdles and NASDAQ compliance issues.

Key Takeaways ProPhase Labs reported an EPS of -0.13, beating the forecast of -0.18. Revenue fell short of expectations, with actual figures at $1.43 million versus a forecast of $2.45 million. The ...